Progression Evaluation and Genetic Determinants of Hypertension in Chinese - A Follow-up Study of Taiwan SAPPHIRe
1 other identifier
observational
1,246
1 country
1
Brief Summary
The purpose of this study is to determine the progression evaluation and genetic determinations of hypertension in Chinese
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2001
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2001
CompletedFirst Submitted
Initial submission to the registry
December 1, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2005
CompletedFirst Posted
Study publicly available on registry
December 2, 2005
CompletedApril 7, 2016
August 1, 2009
4.6 years
December 1, 2005
April 5, 2016
Conditions
Eligibility Criteria
A follow-up genetic study of Taiwan SAPPHIRe Cohort
You may qualify if:
- Age of subjects when recruited must be between 35 and 60 years. Subjects over age 60 may also be eligible provided that documentation of their hypertension status prior to age 60 is available.
- Chinese ancestry, i.e. all four grandparents Chinese. Hypertension is defined as follows: systolic BP (SBP) greater than or equal to (\>=) 160 mm Hg or diastolic BP (DBP) \>= 95 mm Hg or taking 2 medications for high blood pressure (Stage II hypertension). Alternatively the subject could have uncontrolled hypertension, i.e. taking 1 medication for high blood pressure and has either systolic BP \>= 140 or diastolic \>= 90 mm Hg.
You may not qualify if:
- One of the affected sibs is adopted (i.e. no parent in common) or if the sibs have only one parent in common.
- A body-mass index greater than 35.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- National Health Research Institutes, Taiwanlead
- National Taiwan University Hospitalcollaborator
- Tri-Service General Hospitalcollaborator
- Taipei Veterans General Hospital, Taiwancollaborator
- Taichung Veterans General Hospitalcollaborator
Study Sites (1)
Division of Biostatistics and Bioinformatics, NHRI
Miaoli County, Taiwan
Related Publications (1)
Lee IT, Chiu YF, Hwu CM, He CT, Chiang FT, Lin YC, Assimes T, Curb JD, Sheu WH. Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study. Cardiovasc Diabetol. 2012 Apr 26;11:43. doi: 10.1186/1475-2840-11-43.
PMID: 22537054DERIVED
Biospecimen
Plasma, serum, urine, and buffy coat
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Chao Hsiung, PhD
Division of Biostatistics and Bioinformatics, National Health Research Institutes
Study Design
- Study Type
- observational
- Observational Model
- FAMILY BASED
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 1, 2005
First Posted
December 2, 2005
Study Start
May 1, 2001
Primary Completion
December 1, 2005
Study Completion
December 1, 2005
Last Updated
April 7, 2016
Record last verified: 2009-08